Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P18507

UPID:
GBRG2_HUMAN

ALTERNATIVE NAMES:
GABA(A) receptor subunit gamma-2

ALTERNATIVE UPACC:
P18507; F5HB82; Q6GRL6; Q6PCC3; Q9UDB3; Q9UN15

BACKGROUND:
The Gamma-aminobutyric acid receptor subunit gamma-2 is a critical component of the GABA(A) receptor, mediating synaptic inhibition through its chloride channel activity. It is involved in the rapid formation of active synaptic contacts, with its synaptogenic effect varying based on the receptor pentamer composition. Additionally, it functions as a histamine receptor, indicating its multifunctional role in neurotransmission.

THERAPEUTIC SIGNIFICANCE:
Given its association with a spectrum of epilepsy syndromes, Gamma-aminobutyric acid receptor subunit gamma-2 represents a promising target for therapeutic intervention. The protein's link to diseases such as Developmental and epileptic encephalopathy 74 and Generalized epilepsy with febrile seizures plus 3 highlights the potential for developing targeted treatments that could alleviate symptoms and improve quality of life for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.